ACCD Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 0.37%, SMA50 1.02%, SMA200 47.02%). The stock’s 14-day RSI is 70.69 (overbought), while the ATR of 0.03 points to tighter daily ranges. The stock remains hovering near 52-week lows, trading -27.4% below its high and over 127.92% above its low.

Accolade, Inc. generated EPS of -$2.25 over the past year. Five-year average earnings growth is -2.85%. Wall Street analysts project EPS growth of 30.84% annually over the next five years. The latest quarter delivered EPS of -$0.10. The next quarter is forecast at $0.07. Next year's EPS is expected at $13.74. Accolade, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended April 24, 2025, missed forecasts by -300.0%. The prior quarter beat by -6.25%. Over the last six quarters, Apple has recorded several small beats. These include -39.13% in January 08, 2024.

Accolade, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.03. This means the shares are trading below this model’s fair value.

Accolade, Inc. has 81.99 million shares outstanding. The public float is 63.86 million shares, elevated short interest at 2.55% of float. This equals 2.03 million shares. The short ratio is 1.52 days. Institutional investors hold 91.19% of the float. Insiders own 3.28%. SINGH RAJEEV holds 831.96 thousand shares, Barnes Stephen H. has 306.87 thousand shares and Cavanaugh Robert N has 222.22 thousand shares.

The stock is currently mid-range between its 52-week high and low $3.08 and $9.67. With a market capitalization of about $575.59 million, Accolade, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~2.10). Key stats such as the average daily volume over the past year has been around 1.57 million shares, trading with heavier-than-usual volume. Headquartered in Plymouth Meeting, PA, Accolade, Inc. operates in the Healthcare sector and the Medical - Healthcare Information Services industry. Led by CEO Rajeev Singh, the company employs approximately 2,400 people and listed since July 01, 2020. Accolade, Inc., together with its subsidiaries, develops and provides technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States.

Our AI price prediction model suggests that Accolade, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.28%, with price expected at $7.04 by April 21, 2025, within a range of $6.90 to $7.18 1-Year Outlook: Projected gain of 185.75%, with price at $20.06 by April 07, 2026, within a range of $7.76 to $29.74.

Accolade, Inc. (NASDAQ:ACCD) shares are up 105.26% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Accolade, Inc. trading at a premium to the broader market with a P/E of -3.9. Analyst sentiment is cautious, with the majority of ratings in Equal-Weight territory and a mean price target of $17.55, suggesting 150.0% upside.

Accolade, Inc. trades at a P/E ratio of -3.9, slightly below the S&P 500 average, with a price-to-sales ratio of 2.72 and a price-to-book ratio of 1.81 suggesting the stock is closer to book value. The P/FCF stands at -123.2, also below market averages.